Patents Examined by Johnnie R. Brown
  • Method of diagnosing senile dementia of the Alzheimer type
    Patent number: 5200324
    Abstract: A method is provided for the screening of senile dementia of the Alzheimer type (Alzheimer's disease) by testing for an anomalous molecular form of acetylcholinesterase in cerebrospinal fluid of a patient.
    Type: Grant
    Filed: August 1, 1991
    Date of Patent: April 6, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Dasakumar S. Navaratnam, John D. Priddle, Brendon I. McDonald, A. David Smith, Kim A. Jobst
  • 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine
    Patent number: 5198539
    Abstract: The present invention relates to a 3'-substituted pyrimidine nucleoside and its use in medical therapy, particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations.
    Type: Grant
    Filed: August 15, 1991
    Date of Patent: March 30, 1993
    Assignee: Burroughs Wellcome Co.
    Inventors: Saad G. Rahim, Thomas A. Krenitsky
  • Macrophage cytotoxin compositions and methods of preparation
    Patent number: 5198428
    Abstract: This invention provides a cytotoxin composition that inhibits mitochondrial respiration and causes cytostasis in cells, independent of nitric oxide. The invention comprises a conditioned supernatant derived from macrophage cell line (EA13.5) that inhibits mitochondrial respiration and causes cytostasis in cells. More particularly, the invention comprises a macrophage cytotoxin obtained from conditioned supernatant collected from cultured EA13.5 cell. This macrophage cytotoxin (1) inhibits mitochondrial respiration, (2) causes cytostasis independent of L-arginine derived nitric oxide, (3) is a weakly acidic (pI of about 7.5 to 8.0) glycoprotein (as determined by binding to lentil lectin sepharose). The invention also discloses a method for producing an L-arginine-derived nitric oxide-independent macrophage cytotoxin by culturing EA13.5 cells, adding IFN-.gamma.
    Type: Grant
    Filed: April 5, 1991
    Date of Patent: March 30, 1993
    Assignee: Board of Regents, The Univ. of Texas System
    Inventors: Mathoor Sivaramakrishnan, Stanley D. Tucker, Jim Klostergaard, Gabriel Lopez-Berestein
  • Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
    Patent number: 5198465
    Abstract: A composition based on aminoacids and free from hydroxy-proline or hydroxy-lysine useful for preventing and treating precursors deficiencies in the synthesis of collagen comprising proline, glycine, lysine, vitamin C, and one or more compounds selected in the group consisting of .alpha.-ketoglutaric acid, methionine, cysteine, cystine, valine as well as pharmaceutically acceptable diluents and excipients is described.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: March 30, 1993
    Inventor: Francesco S. Dioguardi
  • Natural intense sweeteners
    Patent number: 5198427
    Abstract: The present invention relates to novel sweet compounds derived from the leaves of the subtropical weed Abrus precatorius, and their use as sweeteners. In particular, the present invention contemplates four novel sweet compounds isolated from A. precatorius or A. fruticulosus, and particularly, Abrusosides A, B, C and D and related compounds. The present invention also contemplates the use of these abrusosides and related compounds as sugar substitutes. The present invention contemplates the use of Abrusosides A-D as individual components or in mixtures, in a method for sweetening comestibles, foodstuffs, beverages and medicinal agents.
    Type: Grant
    Filed: July 9, 1990
    Date of Patent: March 30, 1993
    Assignee: Research Corporation Technologies, Inc.
    Inventors: A. Douglas Kinghorn, Young-Hee Choi
  • Process for the preparation of oligonucleotides in solution
    Patent number: 5198540
    Abstract: Process for the preparation of oligonucleotides by successive linking of individual or several nucleoside and/or nucleotide units in a homogeneous phase system using a bi-, tri- or tetra-functional carrier molecule of the general formula Sp(X).sub.n, wherein X is a reactive group which is compatible from the point of view of nucleotide chemistry and n is an integer from 2 to 4, the sequence SP(X-N.sup.1 -N.sup.2 . . . N.sup.m).sub.n being built up stepwise on the carrier molecule and the oligonucleotide of the formula N.sup.1 -N.sup.2 . . . N.sup.m subsequently being released.
    Type: Grant
    Filed: June 19, 1989
    Date of Patent: March 30, 1993
    Inventor: Hubert Koster
  • Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
    Patent number: 5198214
    Abstract: A process for the production of a polyvalent vaccine effective in the prevention and treatment of mastitis in bovine animals is disclosed, which comprises periodically culturing the milk of animals exhibiting preclinical mastitis to cultivate any pathogens present therein, killing those pathogens and incorporating each strain of cultivated, killed pathogen in a pharmacological carrier together with all other strains previously identified. The process is repeated to ensure all newly appearing pathogenic strains are vaccinated against. The vaccine so produced has been demonstrated to be effective in reversal of hard udder syndrome.
    Type: Grant
    Filed: March 18, 1988
    Date of Patent: March 30, 1993
    Assignee: Stolle Research & Development Corporation
    Inventors: Ralph J. Stolle, Lee R. Beck
  • Composition for controlling mastitis in ruminants, method for its preparation and method of treatment of ruminants
    Patent number: 5198215
    Abstract: The invention presents a composition for controlling mastitis in ruminants, a method for preparing the composition and a method of treatment of ruminants. The composition contains one or more soluble exoantigens of gram-positive bacteria involved in mastitis, or immunochemical homologues thereof, in a modified form which creates or enhances their ability to induce acquired mammary hypersensitivity. Said composition may be used as a vaccine or as part of a vaccine for ruminants.
    Type: Grant
    Filed: September 17, 1991
    Date of Patent: March 30, 1993
    Assignee: Noordzee Laboratorium N.V.
    Inventor: Bernard J. C. H. De Cueninck
  • CDNA clone for T-cell suppressor inducer factor
    Patent number: 5196526
    Abstract: The invention generally discloses the cloning and characterization of a nucleotide sequence encode for at least a part of primate T-cell suppressor inducer factor (TsFl) protein and in particular, a putative gene for TsFl produced by the murine cell line A.1.1. The nucleotide sequence is 2936 bp in length comprising an encoding sequence 2565 bp in length and encoding a protein of 690 amino acids.
    Type: Grant
    Filed: November 28, 1989
    Date of Patent: March 23, 1993
    Assignee: University of Health Sciences/The Chicago Medical School
    Inventor: Kenneth D. Beaman
  • Anthracycline analogues bearing latent alkylating substituents
    Patent number: 5196522
    Abstract: The present invention is a compound having the structure ##STR1##Work relating to the development of the present invention was supported by Grant CA 42708 from the National Institutes of Health, DHHS. This support gives the United States Government certain rights in the present invention .
    Type: Grant
    Filed: November 1, 1990
    Date of Patent: March 23, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: David Farquhar, Abdallah Cherif
  • Hydrogen phosphonodithioate compositions
    Patent number: 5194599
    Abstract: Novel hydrogen-phosphonodithioate compositions are provided which are particularly useful for forming internucleotide and internucleoside linkages in oligonucleosides or oligonucleotides. The oligonucleotides and analogs thereof made by using the hydrogen-phosphonodithioate compositions may be therapeutically useful as antiviral and anticancer agents and may have other therapeutic or diagnostic uses. A method for making the hydrogen-phosphonodithioates is provided as well as a method for converting same to an activated intermediate for substitution on the phosphorus atom.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: March 16, 1993
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian C. Froehler, Chris A. Buhr
  • Inhibition of influenza virus replication by oligonucleotide phosphorothioates
    Patent number: 5194428
    Abstract: A method of inhibiting influenza virus replication through the activity of natural (unmodified) or modified oligonucleotides (oligodeoxynucleotides or oligoribonucleotides) which hybridize to a selected region of the influenza virus RNA and interfere with its ability to serve as a template for synthesis of encoded products. Oligonucleotides (unmodified or modified) which have antiviral activity against influenza virus as a result of their ability to hydridze to a selected region of influenza virus RNA and inhibit its ability to serve as a template for synthesis of encoded products, as well as compositions which include the oligonucleotides.
    Type: Grant
    Filed: April 30, 1990
    Date of Patent: March 16, 1993
    Assignees: Worcester Foundation for Experimental Biology, Mt. Sinai School of Medicine
    Inventors: Sudhir Agrawal, Josef M. E. Leiter, Peter Palese, Paul C. Zamecnik
  • Stabilized proteolytic solution and reagent kit
    Patent number: 5192657
    Abstract: A stabilized proteolytic solution has been developed which can be used to treat selected cells, especially red blood cells. A preferred stabilized solution of the invention comprises about 0.1% to about 0.3% ficin in a citrate-buffered saline solution containing mannitol, L-cysteine, dithiothrietol in an active concentration of less than about 10 mM, and EDTA. A kit for qualitatively identifying unexpected blood group antibodies comprising a series of untreated and ficin-treated red blood cells, a stabilized ficin reagent, a red blood cell diluent and an enzyme control is also provided.
    Type: Grant
    Filed: December 18, 1990
    Date of Patent: March 9, 1993
    Assignee: Ortho Diagnostic Systems, Inc.
    Inventors: Janice Jakway, Dennis Mochnal
  • Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
    Patent number: 5192540
    Abstract: Immunogenic conjugates of a 38,000 daltons or 40,000 daltons outer membrane protein of H. influenzae type b and oxidized polyribosyl-ribitol-phosphate polysaccharide fragments of H. influenzae type b are disclosed. Vaccines containing the conjugates are disclosed as useful in immunizing against H. influenzae type b caused disease. Method for isolating and purifying the 38,000 daltons and 40,000 daltons outer membrane proteins and for preparing the oxidized polyribosyl-ribitol-phosphate polysaccharide fragments are also disclosed.
    Type: Grant
    Filed: February 21, 1989
    Date of Patent: March 9, 1993
    Assignee: American Cyanamid Company
    Inventors: Joseph S. Kuo, James E. Bristol
  • Infectious bursal disease virus production in continuous cell lines
    Patent number: 5192539
    Abstract: Infectious bursal disease virus vaccine free of avian cell material comprising inactivated virus or live virus that induces a protective immune response when administered to poultry by noninjection means.
    Type: Grant
    Filed: May 11, 1989
    Date of Patent: March 9, 1993
    Assignee: Akzo N.V.
    Inventors: Piet Van Der Marel, Pieter G. Mooren
  • Process for the glycosylation of avermectin compounds
    Patent number: 5192671
    Abstract: Avermectin compounds are glycosylated the 4' and 4"-positions by adding the avermectin compounds to the fermentation medium of Saccharapolyspora erythrea. The outer oleandrose sugar group of the avermectin compound is glycosylated with a glycosyl moiety, specifically a glucose group. In addition, other changes are effected in the avermectin moiety such as selective hydroxylation, epimerization at the 2-carbon and migration of the .DELTA. 3-double bond to a .DELTA. 2-position.
    Type: Grant
    Filed: June 26, 1991
    Date of Patent: March 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Byron H. Arison, Marvin D. Schulman, Patrick J. Doherty
  • Tissue sealant product and method
    Patent number: 5192542
    Abstract: A product and method of treating tissue particularly during the embalming process. The product is produced by drying and finely grinding plants from the Plantain family to a powder. The method involves applying the powder to wounds, incisions and the like to form closure.
    Type: Grant
    Filed: February 2, 1990
    Date of Patent: March 9, 1993
    Inventors: James J. Hubbs, Jonathan Hubbs
  • Antibiotics unphenelfamycin and phenelfamycins A-D
    Patent number: 5192748
    Abstract: New antibiotics, unphenelfamycin and phenelfamycins A-D, are produced by microorganisms belonging to the genus Streptomyces. The antibiotics have antibacterial activity against gram-positive and gram-negative anaerobic organisms and are effective in improving the feed efficiency and growth rate of livestock, including poultry.
    Type: Grant
    Filed: August 5, 1991
    Date of Patent: March 9, 1993
    Assignee: Abbott Laboratories
    Inventors: Jill E. Hochlowski, Mark H. Buytendorp, Randal H. Chen, James B. McAlpine, Robert J. Theriault, Marianna Jackson, James P. Karwowski
  • Plaque inhibiting oligosaccharide
    Patent number: 5190746
    Abstract: A purified oligosaccharide consisting of a hexasaccharide with a native molecular weight of 959 which can be isolated from the cell walls of Streptococcus oralis. The oligosaccharide is able to significantly block the interaction between the human oral plaque bacteria Streptococcus oralis H1 and Capnocytophaga ochracea ATCC 33596. This purified oligosaccharide contains saccharide components found to inhibit many know interactions between plaque bacteria and may be effective in prevention, inhibition and reversal of dental plaque deposits. The oligosaccharide may be applied effectively when incorporated in toothpastes, mouth wash, etc.
    Type: Grant
    Filed: September 12, 1991
    Date of Patent: March 2, 1993
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Frederick J. Cassels, Jack London
  • Lipid A monosaccharide analogues
    Patent number: 5191072
    Abstract: Lipid A monosaccharide analogues of the following general formula: ##STR1## wherein R.sub.1 is a hydrogen atom or a hydroxyl group, 1 is an integer of 8-14, m is an integer of 11-17 integer, and n is 8-14 integer.
    Type: Grant
    Filed: July 17, 1991
    Date of Patent: March 2, 1993
    Assignees: Japan Tobacco Inc., Akira Hasegawa
    Inventors: Akira Hasegawa, Makoto Kiso, Shinichi Uesato, Masanobu Suzuki, Tomio Ishida, Yutaka Saito